medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2023, Number 4

<< Back Next >>

Arch Neurocien 2023; 28 (4)

Prevalence of treatment resistant depression: TRAL study sub analysis in a Mexican sample

Vázquez-Hernández JL, Alviso-de la Serna LD, Cruz C, Becerra-Palars C, Ibarreche-Beltrán J, Kanevsky G, Cabrera P

Language: English
References: 25
Page: 22-28
PDF size: 204.94 Kb.


ABSTRACT

Introduction: Epidemiology and burden of disease for psychiatric disorders in Latin America (LatAm) is often limited, particularly for conditions like treatment-resistant depression (TRD), which is a burdensome condition within a significant proportion of major depressive disorder (MDD) patients. The treatment resistant depression in America Latina (TRAL) study aimed to investigate the epidemiology and burden of TRD in MDD patients. This paper focuses on characterizing TRD in the Mexican subset using TRAL study data. Methods: The study included 697 adult patients clinically diagnosed with MDD from 14 sites in Mexico. Patients with relevant psychiatric comorbidities or those enrolled in a clinical trial were excluded. Outcomes primarily relied on patient-reported data and assessment scales. Results: TRD prevalence in Mexico was found to be 20.7%. Current suicidality was high in TRD patients (20.8%), as was the incidence of suicide behavior disorder (12.5%). Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) were the most commonly prescribed medications. EQ-5D, SDS and WPAI results indicated significant limitations for TRD patients in their everyday life. Discussion: These findings align with available literature on treatment approaches and the prevalence of suicidality and suicide behavior disorder. The high prevalence of TRD among MDD patients poses a management challenge. Conclusions: The burden of TRD in Mexico is significant, although less severe than in other LatAm countries. Public health policies should focus on improving diagnosis and availability to more effective therapies.


REFERENCES

  1. Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299-312. doi: 10.1016/S0140-6736(18)31948-2

  2. Storeng SH, Sund ER, Krokstad S. Factors associated with basicand instrumental activities of daily living in elderly participants ofa population-based survey: The Nord-Trřndelag Health Study,Norway. BMJ Open. 2018;8(3): e018942. doi: 10.1136/bmjopen-2017-018942

  3. Xie H, Chen PW, Zhao L, Sun X, Jia XJ. Relationship betweenactivities of daily living and depression among older adults andthe quality of life of family caregivers. Front Nurs. 2018;5(2):97–104. doi: 10.2478/fon-2018-0013

  4. Castilla-Puentes R, Secin R, Grau A, Galeno R, Feijo de Mello M,Pena N, et al. A multicenter study of major depressive disorderamong emergency department patients in Latin-Americancountries. Depress Anxiety. 2008; 25(12):E199-204. doi:10.1002/da.20380

  5. Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of theclinical, economic, and societal burden of treatment-resistantdepression: 1996–2013. Psychiatr Serv. 2014; 65(8):977-87.doi: 10.1176/appi.ps.201300059

  6. Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M,et al. Epidemiology of adult DSM-5 major depressive disorderand its specifiers in the United States. JAMA Psychiatry. 2018;

  7. 75(4):336-46. doi: 10.1001/jamapsychiatry.2017.46027. Gaynes BN, Warden D, Trivedi MH, Wisniewski SR, Fava M,Rush AJ. What did STAR*D teach us? Results from a large-scale,practical, clinical trial for patients with depression. Psychiatr Serv.2009;60(11):1439-45. doi: 10.1176/ps.2009.60.11.1439

  8. Conway CR, George MS, Sackeim HA. Toward an evidencebased,operational definition of treatment-resistant depression:When Enough is enough. JAMA Psychiatry. 2017;74(1):9-10.doi: 10.1001/jamapsychiatry.2016.2586

  9. Thase M, Connolly R. Unipolar depression in adults: Choosingtreatment for resistant depression - UpToDate; 2019. https://www.uptodate.com/contents/unipolar-depression-in-adultschoosing-treatment-for-resistant-depression#H925759895

  10. Kraus C, Kadriu B, Lanzenberger R, Zarate CA, Kasper S. Prognosisand improved outcomes in major depression: a review. TranslPsychiatry. 2019;9(1):127. doi: 10.1038/s41398-019-0460-3

  11. Johnston KM, Powell LC, Anderson IM, Szabo S, Cline S. Theburden of treatment-resistant depression: A systematic reviewof the economic and quality of life literature. J Affect Disord.2019;242:195-210. doi: 10.1016/j.jad.2018.06.045

  12. Lepine BA, Moreno RA, Campos RN, Couttolenc BF. Treatmentresistantdepression increases health costs and resourceutilization. Braz J Psychiatry. 2012;34(4):379-88. doi:10.1016/j.rbp.2012.05.009

  13. Chow W, Doane MJ, Sheehan J, Alphs L, Le H. Economic burdenamong patients with major depressive disorder: An analysis ofhealthcare resource use, work productivity, and direct and indirectcosts by depression severity. Am J Manag Care. 2019. Availablefrom: https://www.ajmc.com/view/economic-burden-mdd

  14. Soares B, Kanevsky G, Teng CT, Pérez-Esparza R, Bonetto GG,Lacerda ALT, et al. Prevalence and impact of treatment-resistantdepression in Latin America: a prospective, observationalstudy. Psychiatr Q. 2021;92:1797-1815. doi: 10.1007/s11126-021-09930-x

  15. Sheehan DV, Lecrubier Y, Sheehan KH, Janavs J, WeillerE, Keskiner A, et al. The validity of the Mini InternationalNeuropsychiatric Interview (MINI) according to the SCID-P andits reliability. European Psychiatry. 1997;12(5):232-41.

  16. Montgomery SA, Asberg M. A new depression scale designed tobe sensitive to change. Br J Psychiatry. 1979;134:382-9. doi:10.1192/bjp.134.4.382

  17. Kessler RC, Bromet EJ. The epidemiology of depression acrosscultures. Annu Rev Public Health. 2013;34:119-38. doi:10.1146/annurev-publhealth-031912-114409

  18. Jaffe DH, Rive B, Denee TR. The humanistic and economicburden of treatment-resistant depression in Europe: a crosssectionalstudy. BMC Psychiatry. 2019;19(1):247. doi: 10.1186/s12888-019-2222-4

  19. Ivanova JI, Birnbaum HG, Kidolezi Y, Subramanian G, KhanSA, Stensland MD. Direct and indirect costs of employees withtreatment-resistant and non-treatment-resistant major depressivedisorder. Curr Med Res Opin. 2010; 26(10):2475-84. doi:10.1185/03007995.2010.517716

  20. Zhang Q, DiBernardo A, Heerlein K, O’Hara M, BensonC, Gonzalez Martin Moro B, et al. Association of treatmentresistant depression with healthcare resource utilization andphysician satisfaction with disease management. Value Health.2018;21(Supp 1):S188. doi: 10.1016/j.jval.2018.04.1270

  21. Guerra M, Ferri CP, Sosa AL, Salas A, Gaona C, Gonzales V, et al.Late-life depression in Peru, Mexico and Venezuela: The 10/66population-based study. Br J Psychiatry. 2009;195(6):510-5.doi: 10.1192/bjp.bp.109.064055

  22. Borges G, Benjet C, Medina-Mora ME, Orozco R, Wang PS.Treatment of mental disorders for adolescents in Mexico City.Bull World Health Organ. 2008;86(10):757-64. doi: 10.2471/blt.07.047696

  23. Pimentel L. The Importance of Mental Health in the MexicanPublic Health System. Mexican Journal of Medical ResearchICSA. 2019;7(13):1-6. doi: 10.29057/mjmr.v7i13.3794

  24. Kohn R, Ali AA, Puac-Polanco V, Figueroa C, López-Soto V,Morgan K, et al. Mental health in the Americas: an overview ofthe treatment gap. Rev Panam Salud Publica. 2018;42:e165.doi: 10.26633/RPSP.2018.165

  25. Martinez W, Galván J, Saavedra N, Berenzon S. Barriers tointegrating mental health services in community-based primarycare settings in Mexico city: A qualitative analysis. Psychiatr Serv.2017;68(5):497-502. doi: 10.1176/appi.ps.201600141




2020     |     www.medigraphic.com